This laboratory study is collecting and storing samples of tissue and blood from young patients with Hodgkin's lymphoma. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help the study of cancer in the future.
Hodgkin Disease (HD) Banking Study
I. Establish a biologic specimen repository (of tumor tissue, tissue arrays, lymphoblastoid cell lines, host DNA, tumor and host RNA, serum, and plasma) and database linked to clinical features and outcomes from well-characterized cohorts of children and young adults with Hodgkin's lymphoma.
II. Provide specimens from diagnosis, early response evaluation, completion of chemotherapy and radiotherapy, long-term follow up, and relapse to study prognostic factors for early response, relapse, long-term outcomes, and identification of new biological targets for therapy.
OUTLINE: This is a multicenter study.
Patients enrolled on Hodgkin's lymphoma (HL) therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. Serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression.
Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression.
Patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation.
Refractory Childhood Hodgkin LymphomaStage I Childhood Hodgkin LymphomaStage II Childhood Hodgkin LymphomaStage III Childhood Hodgkin LymphomaStage IV Childhood Hodgkin Lymphoma
Histologically confirmed Hodgkin's lymphoma (HL) meeting 1 of the following criteria:
Newly diagnosed, untreated HL (for patients under 22 years of age)
Past or present diagnosis of HL and past or present enrollment on a Children's Oncology Group (COG) or legacy HL clinical trial (for patients of any age)
Children's Hospital and Research Center at Oakland Oakland, California, 94609-1809, United States
UCSF Medical Center-Mission Bay San Francisco, California, 94158, United States
Kaiser Permanente-Oakland Oakland, California, 94611, United States
Children's Hospital Central California Madera, California, 93636-8762, United States
University of California Davis Comprehensive Cancer Center Sacramento, California, 95817, United States
Sutter General Hospital Sacramento, California, 95816, United States
Santa Barbara Cottage Hospital Santa Barbara, California, 93102, United States
Children's Hospital Los Angeles Los Angeles, California, 90027, United States
Southern California Permanente Medical Group Downey, California, 90242, United States
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Torrance, California, 90502, United States
David Geffen School of Medicine at UCLA Los Angeles, California, 90095, United States
Mattel Children's Hospital UCLA Los Angeles, California, 90095, United States
Miller Children's and Women's Hospital Long Beach Long Beach, California, 90806, United States
Childrens Hospital of Orange County Orange, California, 92868, United States
Loma Linda University Medical Center Loma Linda, California, 92354, United States
Summerlin Hospital Medical Center Las Vegas, Nevada, 89144, United States
University Medical Center of Southern Nevada Las Vegas, Nevada, 89102, United States
Nevada Cancer Research Foundation CCOP Las Vegas, Nevada, 89106, United States
Children's Specialty Center of Nevada II Las Vegas, Nevada, 89109, United States
Sunrise Hospital and Medical Center Las Vegas, Nevada, 89109, United States